aAll participants in the letermovir group received acyclovir for prophylaxis of herpes simplex and varicella zoster virus.
bParticipants were only counted once for the composite safety outcome of ≥1 leukopenia or neutropenia event. P < .001. P value and 95% CI based on the Miettinen and Nurminen method.
cNumber of events is shown by time period: day 1 to week 14, week 14 to week 28, and week 28 to 14 days after prophylaxis was completed. Data were censored at the time of last assessment.